VistaGen Therapeutics (NASDAQ:VTGN) Shares Pass Below 50-Day Moving Average – Here’s What Happened

VistaGen Therapeutics, Inc. (NASDAQ:VTGN)’s share price crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $0.25 and traded as low as $0.24. VistaGen Therapeutics shares last traded at $0.2434, with a volume of 319,344 shares.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VistaGen Therapeutics in a research note on Monday, August 31st. Four investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, VistaGen Therapeutics presently has a consensus rating of “Reduce” and a consensus price target of $0.95.

VistaGen Therapeutics Trading Up 0.2%

The firm has a market capitalization of $10.80 million, a P/E ratio of -0.15 and a beta of 0.39. The stock has a 50 day simple moving average of $0.25 and a 200-day simple moving average of $0.48.

VistaGen Therapeutics (NASDAQ:VTGN) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.06. The firm had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $0.50 million. VistaGen Therapeutics had a negative net margin of 2,702.64% and a negative return on equity of 152.59%. As a group, sell-side analysts expect that VistaGen Therapeutics, Inc. will post -1.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its stake in shares of VistaGen Therapeutics by 1,068.0% during the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after acquiring an additional 19,331 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in VistaGen Therapeutics in the 1st quarter worth $25,000. Marshall Wace LLP purchased a new position in VistaGen Therapeutics during the second quarter valued at $69,000. Jane Street Group LLC purchased a new position in VistaGen Therapeutics during the second quarter valued at $190,000. Finally, Dimensional Fund Advisors LP grew its holdings in VistaGen Therapeutics by 56.9% during the third quarter. Dimensional Fund Advisors LP now owns 68,017 shares of the company’s stock valued at $241,000 after purchasing an additional 24,655 shares during the period. 78.39% of the stock is currently owned by institutional investors.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.